You are here

Novartis

Novartis taps Vyriad’s viral vectors to develop in vivo T cell editing

Fierce Biotech

Wed, 11/20/24 - 08:44 pm

Novartis, Ratio sign radiopharmaceutical pact to the tune of $745M biobucks

Fierce Biotech

Mon, 11/18/24 - 11:32 am

radiopharmaceuticals

Ration Therapeutics

FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions

CP Wire

Thu, 11/14/24 - 10:25 pm

FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions

Thu, 11/14/24 - 07:28 pm

Novartis pays Schrödinger $150M, bets billions on the back end to form drug discovery pact

Fierce Biotech

Tue, 11/12/24 - 11:02 am

Autolus enters CAR-T race with FDA approval for Aucatzyl

Fierce Pharma

Mon, 11/11/24 - 11:49 am

Autolus Therapeutics

Gilead Sciences

relapsed or refractory B-cell precursor acute lymphoblastic leukemia

Among 2024’s modest M&A action, cancer, immunology and neuroscience deals trickle in

Pharma Voice

Thu, 11/7/24 - 11:12 am

Vertex Pharmacuticals

Alpine Immune Sciences

Mariana Oncology

Fusion Pharmaceuticals

Longboard Pharmaceuticals

Aliada Therapeutics

In defense of radioligand therapies, Novartis fired off patent lawsuits against Lilly and other rivals

Fierce Pharma

Mon, 11/4/24 - 11:21 am

radiopharmaceuticals

Big Pharma earnings hang hope on the next generation of blockbusters

Pharma Voice

Thu, 10/31/24 - 09:19 am

Novartis gets FDA okay for frontline use of Scemblix in CML

Pharmaphorum

Wed, 10/30/24 - 11:38 am

Novartis' $2.9B MorphoSys bet stumbles as safety signal delays filing by years

Fierce Biotech

Tue, 10/29/24 - 11:44 am

Monte Rosa joins with Novartis in ‘molecular glue’ drug deal

BioPharma Dive

Mon, 10/28/24 - 11:36 am

molecular glue degrader

Novartis eyes year-end filing in US for Fabhalta in C3G

Pharmaphorum

Mon, 10/28/24 - 10:17 am

C3 glomerulopathy

Novartis falls short in legal effort to undo FDA approval of MSN's Entresto generic

Fierce Pharma

Thu, 10/17/24 - 08:50 pm

MSN Pharmaceuticals

Novartis loses latest bid to block generic version of blockbuster heart drug

Reuters

Thu, 10/17/24 - 09:26 am

1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move

Motley Fool

Thu, 10/17/24 - 09:24 am

Novartis terminating midphase SMURF1 trial

Fierce Biotech

Mon, 10/14/24 - 10:19 am

clinical trials

Novartis inks $1B-plus biobucks deal with Flagship's Generate

Fierce Biotech

Tue, 09/24/24 - 11:41 am

Generate Biomedicines

protein therapeutics

Novartis not joining the ‘frenzy’ of weight loss drugs, CEO says

CNBC

Thu, 09/19/24 - 11:13 am

Novartis heaps pressure on Lilly with broad FDA approval for Kisqali in early breast cancer

Fierce Pharma

Tue, 09/17/24 - 11:08 pm

Pages